Drug Trial Radar · NCT05987033
Proof-of-concept Study With NVDX3 for Treatment of Distal Radius Fractures.
Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
11
Actual
Start
Aug 8, 2023
Primary completion
Dec 19, 2024
Study completion Dec 19, 2024
Sponsor
- Lead sponsor
- Novadip BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prospective, single arm, monocentric clinical study to test NVDX3 in patients suffering from distal radius fracture. NVDX3 will be implanted during a single surgical intervention.
Conditions
- Distal Radius Fractures
Interventions
NVDX3Drug
NVDX3 is implanted during a single surgical intervention.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: Serious Treatment-emergent Adverse Events (TEAEs) and NVDX3-related TEAEsTime frame: Between the beginning of the implant surgery (IS) and 12 months post-IS
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Centre Hospitalier de Luxembourg
Luxembourg, Luxembourg
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.